Phase 2 N=64 A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
Pterygium
Primary: Change From Baseline in Overall Conjunctival Hyperemia Score — -0.056; -0.330; -0.352 score on a scale — p=0.218
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=115 Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium
Pterygium
Primary: Number of Pterygium Hyperemia Responders at Week 16 — 6; 8 Participants
Phase 2 N=5 The Effect of Bevacizumab (Avastin) on Pterygium
Pterygium
Primary: The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. — 5.75 area in millimeters squared…
Phase 2 N=75 Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Pterygium
Primary: Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale — 0; -0.8 grade — p=<0.001
Phase 2 N=39 Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
Pterygium
Primary: Number of Participants Who Had Recurrence of Pterygia up to 1 Year — 0; 3 participants
N/A N=96 Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane
Recurrent Pterygium
Primary: Recurrence — 46; 34; 0; 3 eyes — p=<0.05
Phase 4 N=166 Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
Pterygium · Ocular Pain · Ocular Inflammation
Primary: Conjunctival Hyperemia (CH) — 0; 0; 39; 29 eyes — p=0.133
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
Phase 2 N=20 Treatment of Corneal Neovascularization With Topical Pazopanib
Corneal Neovascularization
Primary: Heart Rate — 68.7 Beats per Minutes
N/A N=21 Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye
Dry Eye · Dry Eye Syndromes
Primary: Ocular Surface Tear Breakup Time — 3.81; 2.91 seconds — p=<0.01
N/A N=30 Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds
Lid-Parallel Conjunctival Folds
Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score
Phase 2 N=20 Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Polypoidal Choroidal Vasculopathy
Primary: Commonly Reported and Notable Adverse Events — 1; 2; 2; 3 participants
Phase 2 N=124 PRM-151 in the Prevention of Scarring Following Trabeculectomy
Glaucoma
Primary: Safety of Subconjunctival Injection — 274; 220; 166; 113 Number of occurrences
N/A N=40 Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy
Corneal Wound Healing
Primary: Number of Days to Complete Re-epithelialization — 4.6; 4.1 days to complete re-epithelialization
Phase 4 N=333 Aflibercept in Polypoidal Choroidal Vasculopathy
Neovascular Macular Degeneration
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…
N/A N=30 Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain
Pain · Vision Nearsighted
Primary: Number of Participants With Pain Score of Four or Greater. Score Range: 0-10, Higher Score Corresponds to More Pain. — 0 Participants
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 2 N=6 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Retinal Diseases · Telangiectasis
Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit
Phase 4 N=242 Primary Tube Versus Trabeculectomy Study
Glaucoma
Primary: Number of Participants With Surgical Failure — 31; 23; 18; 9 Participants